Recombinant exopeptidases that degrade gluten

AMYRA Biotech is focused on developing innovative solutions for gluten-related health disorders through a unique interdisciplinary approach that combines computational biochemistry, drug delivery, and analytics. The company addresses the challenges of gluten peptide digestion, particularly for individuals with conditions like celiac disease and non-celiac gluten sensitivity. AMYRA's research emphasizes the importance of effectively degrading gluten immunogenic peptides (GIPs), which can lead to inflammatory responses when digestion is incomplete. By collaborating with research institutes and healthcare professionals, AMYRA aims to enhance the understanding of dietary proteins' roles in gastrointestinal disorders.

The company's flagship products, AMYNOPEP 01 and AMYNOPEP 02, are designed to provide therapeutic solutions for non-celiac gluten sensitivity and celiac disease, respectively. AMYNOPEP 01 utilizes a specific combination of exopeptidases to break down immunogenic polypeptides into harmless amino acids and dipeptides, while AMYNOPEP 02 is formulated to rapidly degrade GIPs, thereby inhibiting immune responses in celiac patients. Additionally, AMYRA is developing a novel diagnostic tool to assess gluten digestion in affected individuals, further solidifying its commitment to improving the quality of life for those with gluten-related health issues.

Switzerland

AMYRA Biotech AG is a Swiss based, privately held biotech company that develops novel, enzyme-based treatments for celiac disease and non-celiac gluten sensitivity. AMYRA's patented technology could transform the lives of millions of people around the globe and provide a new gold standard for treating gluten related disorders.

AMYRA Biotech

Company Details